Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTX-343
- Development stage
- Preclinical
- Lead developer
- Contineum Therapeutics
- Modality
- Small Molecules
01
Overview
CTX-343 is a peripherally restricted small molecule antagonist of the lysophosphatidic acid receptor 1 (LPA1R). It is being developed by Contineum Therapeutics as an anti-inflammatory agent. Unlike some other LPA1 antagonists, CTX-343 does not cross the blood-brain barrier and is designed to act on peripheral tissues. The drug is currently in preclinical development, with plans to file an Investigational New Drug (IND) application with the U.S. FDA in the second half of 2025[1][2][3][4][6]. Its mechanism involves blocking LPA1R signaling, which has been implicated in inflammation and fibrosis.
- Other names
- LPA1R DCLPA-1R DCLPA 1R DC
02
Targets
LPAR1 (Lysophosphatidic acid receptor 1)
Beyond the preview
Go deeper on CTX-343.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTX-343.